Ocular Hypertension

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended marketing authorization approval for Rhokiinsa for the reduction of IOP in primary open-angle glaucoma or ocular hypertension, Aerie Pharmaceuticals announced in a press release.

Aerie Pharmaceuticals has submitted a prior approval supplement to the FDA to allow Rocklatan production in its Athlone, Ireland, facility, according to a press release.

COEUR D’ALENE, Idaho — Glaucoma was strongly associated with higher failure rates after Descemet’s stripping automated endothelial keratoplasty, according to a poster presented at the Women in Ophthalmology Summer Symposium.

Alembic Pharmaceuticals’ abbreviated new drug application for dorzolamide hydrochloride ophthalmic solution USP 2% has been approved by the FDA, according to a press release.

COPENHAGEN — The European Glaucoma Society has issued amended guidelines for the management of primary open-angle glaucoma. For the general ophthalmologist and physician, these updated guidelines provide an overview on the latest outcome evidence, explaining revised practice recommendations for managing patients with glaucoma or ocular hypertension. This article reviews some of the important considerations outlined in the newly revised document.